Warning Letter — Hubei Gedian Humanwell Pharmaceutical Co., Ltd.
The FDA issued a Warning Letter to Hubei Gedian Humanwell Pharmaceutical Co., Ltd. following an inspection by the Center for Drug Evaluation and Research (CDER) that identified significant deviations from current good manufacturing practice (CGMP).
This affects Hubei Gedian Humanwell Pharmaceutical Co., Ltd., its manufacturing personnel, quality control units, and potentially any partners relying on their API or finished drug products.
The issuance of a Warning Letter by CDER indicates that the facility's manufacturing processes do not meet statutory requirements, which can lead to the withholding of drug approvals or the imposition of import bans. This represents a significant regulatory roadblock that typically requires comprehensive remediation and a follow-up inspection to resolve.
Manufacturing and QA teams should conduct thorough internal audits of production documentation and site controls to ensure compliance with CGMP. Regulatory leads for this firm should prepare for potential import alerts or delayed approvals of pending applications until the cited violations are remediated and verified by the FDA.
FDA Warning Letter issued to: Hubei Gedian Humanwell Pharmaceutical Co., Ltd.. 06/03/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hubei-gedian-humanwell-pharmaceutical-co-ltd-725591-06032026
Open in openFDA / FDA.gov